Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed · Phase 2

Conditions studied: Lung Cancer

In brief

RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of soblidotin in treating patients who have progressive locally advanced or metastatic non-small cell lung cancer.

Key facts

Study ID

NCT00061854

Run by

Daiichi Sankyo

Starts

2003-04-01

Expected to finish

2005-05-01

Last updated by the study team

2012-05-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Medical Oncology and Hematology, P.C. — Waterbury, Connecticut, United States
• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.